- Home
- VIR vs PGNY Comparison
VIR vs PGNY Comparison
Compare VIR & PGNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VIR | PGNY |
|---|---|---|
| Founded | 2016 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Misc Health and Biotechnology Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2019 | 2019 |
Fundamental Metrics
Financial Performance| Metric | VIR | PGNY |
|---|---|---|
| Price | $8.40 | $17.28 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 10 |
| Target Price | $19.63 | ★ $26.50 |
| AVG Volume (30 Days) | ★ 3.5M | 1.7M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17.49 | 14.04 |
| EPS | N/A | ★ 0.65 |
| Revenue | $68,556,000.00 | ★ $1,288,661,000.00 |
| Revenue This Year | N/A | $8.87 |
| Revenue Next Year | $1,049.62 | $9.62 |
| P/E Ratio | ★ N/A | $27.35 |
| Revenue Growth | N/A | ★ 10.40 |
| 52 Week Low | $4.16 | $16.76 |
| 52 Week High | $10.91 | $28.75 |
Technical Indicators
Market Signals| Indicator | VIR | PGNY |
|---|---|---|
| Relative Strength Index (RSI) | 45.05 | 32.79 |
| Support Level | $5.14 | $16.88 |
| Resistance Level | $10.29 | $22.71 |
| Average True Range (ATR) | 0.47 | 0.70 |
| MACD | -0.18 | 0.16 |
| Stochastic Oscillator | 3.20 | 15.62 |
Price Performance
Historical ComparisonAbout VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
About PGNY Progyny Inc.
Progyny Inc is a benefits management company specializing in fertility, family building, and women's health benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments, and active management of the selective network of high-quality provider clinics.